Back

C4X Discovery to receive $13 million milestone from AstraZeneca

Verifying
  • C4X Discovery will receive a milestone payment from AstraZeneca after its NRF2 programme entered clinical development.
  • $13 million is payable under the licensing agreement announced in November 2022.
  • AstraZeneca is studying AZD4916 in a Phase I trial involving healthy volunteers.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.